Zametkin A J, Linnoila M, Karoum F, Sallee R
Am J Psychiatry. 1986 Mar;143(3):359-62. doi: 10.1176/ajp.143.3.359.
To test the hypothesis that any change in urinary noradrenergic excretion accompanies drug-induced improvement in attention deficit disorder with hyperactivity, the authors gave pemoline (mean dose, 2.9 mg/kg of body weight) to 11 boys with this disorder in a 4-week open trial. Pemoline administration improved behavior but did not significantly change urinary catecholamine excretion. Serotonin excretion was unchanged, but phenylethylamine (PEA) and 5-hydroxyindoleacetic acid (5-HIAA) were significantly decreased. Clinical responders and nonresponders did not differ with respect to baseline urinary monoamine excretion or change in PEA and 5-HIAA excretion.
为了验证尿去甲肾上腺素能排泄的任何变化都伴随着药物诱导的多动性注意力缺陷障碍改善这一假设，作者在一项为期4周的开放试验中，给11名患有该障碍的男孩服用匹莫林（平均剂量为2.9mg/kg体重）。服用匹莫林改善了行为，但并未显著改变尿儿茶酚胺排泄。血清素排泄未变，但苯乙胺（PEA）和5-羟吲哚乙酸（5-HIAA）显著减少。临床反应者和无反应者在基线尿单胺排泄或PEA及5-HIAA排泄变化方面并无差异。
